Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Diluted EPS of $1.26 per share (loss) for fiscal year 2025.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.26 | +20.8% |
| 2024 | -$1.59 | +40.2% |
| 2023 | -$2.66 | +33.3% |
| 2022 | -$3.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | +25.0% | -13.8% |
| June 30, 2025 | -$0.29 | +35.6% | +0.0% |
| March 31, 2025 | -$0.29 | +32.6% | +34.1% |
| September 30, 2024 | -$0.44 | +10.2% | +2.2% |
| June 30, 2024 | -$0.45 | +55.0% | -4.7% |
| March 31, 2024 | -$0.43 | +47.6% | +12.2% |
| September 30, 2023 | -$0.49 | +44.9% | +51.0% |
| June 30, 2023 | -$1.00 | -5.3% | -22.0% |
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +20.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s diluted eps has grown by 68.4% (from $3.99 per share (loss) to $1.26 per share (loss)).
- The most recent figure is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: